Eli Lilly (LLY) shares were down slightly Tuesday despite reporting better-than-expected earnings on both the top and bottom lines for the final quarter of 2023, driven by an expected boost from GLP-1 products Mounjaro and Zepbound. The company is trading at $705 per share, after popping in pre-market trading on the solid results and dropping […]